Banurekha Velayutham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Banurekha Velayutham has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Lavanya Jayabal
Affiliation National Tuberculosis Elimination Programme, Chennai, India
3 shared publicationsDina Nair
Affiliation ICMR- National Institute for Research in Tuberculosis, Chennai, India
2 shared publicationsSanjay Mehendale
ICMR, Head Quarters, New Delhi, India
2 shared publicationsAmmayappan Radhakrishnan
ICMR- National Institute for Research in Tuberculosis, Chennai, India
1 shared publicationAngamuthu Dhanalakshmi
ICMR- National Institute for Research in Tuberculosis, Chennai, India
1 shared publicationAsha Frederick
District Tuberculosis Officer, District Tuberculosis Centre, Dharmapuri District, Tamil Nadu, India
1 shared publication
Latest Publications
- Open Access
- 29 January 2021
- Published by Wiley in Tropical Medicine & International Health
- Vol. 26 (5) , 608
Authors’ Response to ‘False equivalence of four month and six‐month ATT regimen: a case of comparing apples and oranges’
Malegaonkar et al. have raised concerns on two issues with reference to our paper entitled ‘4‐month moxifloxacin containing regimens in the treatment of patients with sputum‐positive pulmonary tuberculosis in South India ‐ a randomised clinical trial’ in the letter ‘False equivalence of four month and six‐month ATT regimen: A case of comparing apples and oranges’. They have flagged the use of an intermittent 6‐month regimen as the control arm, and questioned the rationality of using moxifloxacin in the treatment of drug‐susceptible tuberculosis (TB).
- 29 January 2021
- Published by Wiley in Tropical Medicine & International Health
- Vol. 26 (5) , 608
Open AccessAuthors’ Response to ‘False equivalence of four month and six‐month ATT regimen: a case of comparing apples and oranges’
Malegaonkar et al. have raised concerns on two issues with reference to our paper entitled ‘4‐month moxifloxacin containing regimens in the treatment of patients with sputum‐positive pulmonary tuberculosis in South India ‐ a randomised clinical trial’ in the letter ‘False equivalence of four month and six‐month ATT regimen: A case of comparing apples and oranges’. They have flagged the use of an intermittent 6‐month regimen as the control arm, and questioned the rationality of using moxifloxacin in the treatment of drug‐susceptible tuberculosis (TB).
- Open Access
- 15 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240594
Tuberculosis screening in household contacts of pulmonary tuberculosis patients in an urban setting
Household contacts (HHC) of tuberculosis (TB) patients are at risk of TB infection and disease. The study assessed the utility of “Household contact card and register” for screening of HHC of pulmonary TB (PTB) patients for TB and explored the reasons for HHC not being screened and followed-up. The “Household contact card and register” was implemented by the Health Care Workers (HCW) of the TB Control Programme in Chennai District for screening HHC of index PTB patients initiated on treatment between June and August, 2018. Contacts were required to be screened within 2 months of treatment initiation of the index patient. Details collected included age, gender, smoking, alcohol use, immunosuppressive conditions and TB treatment. Symptom screening along with chest radiograph and or sputum examination was attempted. Follow-up TB screening at 6 and 12 months were performed. Screening of HHC was compared pre and post implementation phase. Proportions were computed for the data analysed. HHC information was documented for 93% (1268/1364) of Index PTB patients. The main reasons of non-listing of HHC in 96 PTB patients were HCW non-availability or non-co-operation of the HHC. There were 2150 (80%) contacts who were screened for TB. Inconvenient time, feeling healthy, stigma, out-station visit were the main reasons for 537 contacts not undergoing TB screening. Anti-TB treatment was initiated in 21 (1%) of contacts diagnosed with TB. Preventive therapy was initiated in 59% (81/138) of contacts aged <6 years. The screening of HHC improved from 36% to 80% during the implementation phase. Follow-up TB screening at 12 months was performed in 50% of HHC and 2 incident TB cases were identified. “Household contact card and register” is a useful tool for HCWs for TB screening in HHC of PTB patients. Reasons for non-adherence to contact screening needs to be addressed.
- 15 October 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (10) , e0240594
Open AccessTuberculosis screening in household contacts of pulmonary tuberculosis patients in an urban setting
Household contacts (HHC) of tuberculosis (TB) patients are at risk of TB infection and disease. The study assessed the utility of “Household contact card and register” for screening of HHC of pulmonary TB (PTB) patients for TB and explored the reasons for HHC not being screened and followed-up. The “Household contact card and register” was implemented by the Health Care Workers (HCW) of the TB Control Programme in Chennai District for screening HHC of index PTB patients initiated on treatment between June and August, 2018. Contacts were required to be screened within 2 months of treatment initiation of the index patient. Details collected included age, gender, smoking, alcohol use, immunosuppressive conditions and TB treatment. Symptom screening along with chest radiograph and or sputum examination was attempted. Follow-up TB screening at 6 and 12 months were performed. Screening of HHC was compared pre and post implementation phase. Proportions were computed for the data analysed. HHC information was documented for 93% (1268/1364) of Index PTB patients. The main reasons of non-listing of HHC in 96 PTB patients were HCW non-availability or non-co-operation of the HHC. There were 2150 (80%) contacts who were screened for TB. Inconvenient time, feeling healthy, stigma, out-station visit were the main reasons for 537 contacts not undergoing TB screening. Anti-TB treatment was initiated in 21 (1%) of contacts diagnosed with TB. Preventive therapy was initiated in 59% (81/138) of contacts aged <6 years. The screening of HHC improved from 36% to 80% during the implementation phase. Follow-up TB screening at 12 months was performed in 50% of HHC and 2 incident TB cases were identified. “Household contact card and register” is a useful tool for HCWs for TB screening in HHC of PTB patients. Reasons for non-adherence to contact screening needs to be addressed.
- 1 April 2020
- Published by Wiley in Tropical Medicine & International Health
- Vol. 25 (4) , 483-495
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial
Background Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India. Methods New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H(3)R(3)Z(3)E(3)/4R(3)H(3)) [C]. The 4 test regimens were 3R(7)H(7)Z(7)E(7)M(7) [M3], 2R(7)H(7)Z(7)E(7)M(7)/2R(7)H(7)M(7) [M4], 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)M(3) [M4-I] or 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)E(3)M(3) [M4-IE]. Treatment was directly observed. Clinical and bacteriological assessments were done monthly during treatment and for 24 months post-treatment. The primary end point was TB recurrence post-treatment. Results Of 1371 patients, randomised, modified intention-to-treat (ITT) analysis was done in 1329 and per-protocol (PP) analysis in 1223 patients. Regimen M3 was terminated due to high TB recurrence rates. 'Favourable' response at end of treatment was 96-100% in the moxifloxacin regimens and 93% in the control regimen. Among these, the TB recurrence occurred in 4.1% in the M4 regimen and in 4.5% in the control regimen and demonstrated equivalence within a 5% margin (95% CI -3.68, 4.55). Similar findings were observed in modified ITT analysis. The TB recurrence rates in the M4-I and M4-IE regimens did not show equivalence with the control regimen. Sixteen (1.4%) of 1087 patients in the moxifloxacin regimens required treatment modification. Conclusion The 4-month daily moxifloxacin regimen [M4] was found to be equivalent and as safe as the 6-month thrice-weekly control regimen.
- 1 April 2020
- Published by Wiley in Tropical Medicine & International Health
- Vol. 25 (4) , 483-495
4-month moxifloxacin containing regimens in the treatment of patients with sputum-positive pulmonary tuberculosis in South India - a randomised clinical trial
Background Shortening tuberculosis (TB) treatment duration is a research priority. We tested the efficacy and safety of 3- and 4-month regimens containing moxifloxacin in a randomised clinical trial in pulmonary TB (PTB) patients in South India. Methods New, sputum-positive, adult, HIV-negative, non-diabetic PTB patients were randomised to 3- or 4-month moxifloxacin regimens [moxifloxacin (M), isoniazid (H), rifampicin (R), pyrazinamide (Z) and ethambutol (E)] or to a control regimen (2H(3)R(3)Z(3)E(3)/4R(3)H(3)) [C]. The 4 test regimens were 3R(7)H(7)Z(7)E(7)M(7) [M3], 2R(7)H(7)Z(7)E(7)M(7)/2R(7)H(7)M(7) [M4], 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)M(3) [M4-I] or 2R(7)H(7)Z(7)E(7)M(7)/2R(3)H(3)E(3)M(3) [M4-IE]. Treatment was directly observed. Clinical and bacteriological assessments were done monthly during treatment and for 24 months post-treatment. The primary end point was TB recurrence post-treatment. Results Of 1371 patients, randomised, modified intention-to-treat (ITT) analysis was done in 1329 and per-protocol (PP) analysis in 1223 patients. Regimen M3 was terminated due to high TB recurrence rates. 'Favourable' response at end of treatment was 96-100% in the moxifloxacin regimens and 93% in the control regimen. Among these, the TB recurrence occurred in 4.1% in the M4 regimen and in 4.5% in the control regimen and demonstrated equivalence within a 5% margin (95% CI -3.68, 4.55). Similar findings were observed in modified ITT analysis. The TB recurrence rates in the M4-I and M4-IE regimens did not show equivalence with the control regimen. Sixteen (1.4%) of 1087 patients in the moxifloxacin regimens required treatment modification. Conclusion The 4-month daily moxifloxacin regimen [M4] was found to be equivalent and as safe as the 6-month thrice-weekly control regimen.
- Open Access
- 1 January 2017
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 42 (4) , 238-241
Indicators to ensure treatment initiation of all diagnosed sputum positive pulmonary tuberculosis patients under tuberculosis control programme in India
Background: Pretreatment loss to follow-up (PTLFU) is used as performance indicator of Revised National Tuberculosis Control Programme (RNTCP) of India. Objective: To document the PTLFU, identify additional indicators and examine documentation of all the diagnosed sputum positive pulmonary tuberculosis (PTB) patients under RNTCP. Methodology: Tuberculosis (TB) laboratory, referral for treatment registers, and referral forms were perused for information on sputum positive PTB patients diagnosed from January to June 2014, in 3 TB Units in Chennai. Results: PTLFU was 24% (572 out of 2361). However, in pursuance with the principle of ensuring that all diagnosed patients must be started on treatment following referral, it was inflated to 44% (1046 out of 2361). Conclusion: The existing PTLFU indicator does not reflect the proportion of treatment initiation of all diagnosed smear-positive PTB patients. We propose additional indicators for monitoring referral and treatment initiation of all diagnosed sputum positive PTB patients.
- 1 January 2017
- Published by Medknow in Indian Journal of Community Medicine
- Vol. 42 (4) , 238-241
Open AccessIndicators to ensure treatment initiation of all diagnosed sputum positive pulmonary tuberculosis patients under tuberculosis control programme in India
Background: Pretreatment loss to follow-up (PTLFU) is used as performance indicator of Revised National Tuberculosis Control Programme (RNTCP) of India. Objective: To document the PTLFU, identify additional indicators and examine documentation of all the diagnosed sputum positive pulmonary tuberculosis (PTB) patients under RNTCP. Methodology: Tuberculosis (TB) laboratory, referral for treatment registers, and referral forms were perused for information on sputum positive PTB patients diagnosed from January to June 2014, in 3 TB Units in Chennai. Results: PTLFU was 24% (572 out of 2361). However, in pursuance with the principle of ensuring that all diagnosed patients must be started on treatment following referral, it was inflated to 44% (1046 out of 2361). Conclusion: The existing PTLFU indicator does not reflect the proportion of treatment initiation of all diagnosed smear-positive PTB patients. We propose additional indicators for monitoring referral and treatment initiation of all diagnosed sputum positive PTB patients.
- 1 October 2016
- Published by Elsevier in Disability and Health Journal
- Vol. 9 (4) , 584-592
The prevalence of disability in elderly in India – Analysis of 2011 census data
- 1 October 2016
- Published by Elsevier in Disability and Health Journal
- Vol. 9 (4) , 584-592
The prevalence of disability in elderly in India – Analysis of 2011 census data